PubMed Health⌕ Search

PubMed · 14678859

Hyperglycemia as a cardiovascular risk factor.

Abstract

Patients with type 2 diabetes mellitus have a 2- to 4-fold increased risk of coronary heart disease (CHD) and a 4-fold increase in mortality from CHD. Intensive glycemic control has a more modest effect on reducing macrovascular complications than microvascular complications. Most likely, this is because the development of cardiovascular disease is multifactorial, and hyperglycemia is 1 of many risk factors. Epidemiologic data suggest that a glycosylated hemoglobin (A(1c)) level of < or =7% is reasonable to avoid or minimize the complications associated with type 2 diabetes. Studies have shown that there is an increased risk of cardiovascular mortality before the onset of type 2 diabetes. The presence of CHD before the onset of clinical diabetes provides strong evidence for a strategy of diabetes prevention in at-risk patients. Data indicate that the atherogenic pattern of changes in the prediabetic state is seen primarily in insulin-resistant patients rather than in those with abnormally low insulin secretion. Therefore, strategies to prevent or treat type 2 diabetes should focus on improving insulin sensitivity. Clinical trials have demonstrated that lifestyle changes (e.g., diet and exercise) as well as use of metformin, acarbose, or troglitazone reduce the incidence of type 2 diabetes. Prevention of type 2 diabetes may be an important strategy to delay or prevent cardiovascular disease in many individuals.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Steven J Haffner, Holly Cassells. 2003-12-08. Hyperglycemia as a cardiovascular risk factor.. https://doi.org/10.1016/j.amjmed.2003.09.009

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗